Prosecution Insights
Last updated: November 04, 2026
Application No. 18/270,900

SYSTEM AND METHOD FOR DELIVERING THERAPEUTIC AGENTS TO THE UTERINE CAVITY

Final Rejection §103§112§DP
Filed
Jul 05, 2023
Priority
Jan 18, 2021 — provisional 63/138,556 +1 more
Examiner
MOU, LIYUAN
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gynion LLC
OA Round
2 (Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
53 granted / 121 resolved
-16.2% vs TC avg
Strong +60% interview lift
Without
With
+59.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
82 currently pending
Career history
215
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
14.0%
-26.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 121 resolved cases

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment Acknowledgment is made of the receipt and entry of the amendment filed on 06/19/2026, wherein claims 42, 44, 46-61, 63, 64 and 66-69 are cancelled, new claims 74-80 are added and independent claim 41 is amended. Election/Restriction Applicant did not explicitly elect Group of invention and species in the reply on 12/12/2025. The Examiner searched and examined trichloroacetic acid as the therapeutic agent, Carbopol® as the thickening agent, uterine endometrium as the superficial layer species. Status of Claims Claims 41, 43, 45, 65, and 70-80 are pending and currently under examination in this office action. Priority This instant application 18/270,900 filed 07/05/2023 is a 371 of PCT/US2022/012081filed on 01/12/2022, which claims benefit of US provisional application 63/138,556 filed on 01/18/2021. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. The disclosure of the prior-filed application, Pro application No. 63/138,556 fails to provide adequate support in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. It’s noted US provisional application 63/138,556 only discloses the therapeutic agent is used for treatment of tissue inside of the body, including treatment of various body cavities (See page 5). US provisional application 63/138,556 does NOT disclose following subject matter: composition having pH less than 2 and a viscosity greater than water as recited in claim 41; the amount of thickening agent greater than 3% as recited in instant claims 41 and 78; Composition having pH less than zero as recited in new claim 80. Information Disclosure Statement The information disclosure statement filed 06/19/2026 is being considered by the examiner. Response to Arguments Applicant's remarks filed 06/19/2026 have been fully considered. Any objection and rejection found in the previous Office Action and not repeated herein has been withdrawn in view of amendment and Applicant’s remarks .The text of those sections of Title 35 U.S. Code not included in this action can be found in a prior Office action. As necessitated by the amendment, claims 41, 43, 45, 65, and 70-80 are newly rejected under 35 USC § 112 (a) as failing to comply with written description requirement and 112 (b). Claim Objections Claim 71 is objected to because of the following informalities: There is typo error in claim 71, “between over 3mm and 7mm”. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description Rejection Claims 43, 45, 65, and 70-80 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of instantly claimed method for chemical ablation(newly reapplied as necessitated by amendment). Applicant is directed to the MPEP 2163 and Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, 1st "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001. MPEP 2163.02 states “ Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, the inventor was in possession of the invention, and that the invention, in that context, is whatever is now claimed.” Instant claims are amended to recite a method for chemical ablation of endometrial and myometrial layers of a uterine cavity, comprising applying to tissue a gel-form composition containing trichloroacetic acid and a thickening agent, wherein the therapeutic agent remains on the tissue to penetrate the tissue beyond the superficial layer for ablation of the endometrial and myometrial layers of the uterine cavity, the penetrating of tissue being over 3 millimeters, the viscosity enabling control of flow to target tissue such that upon application to tissue, the composition remains on the target surface within the uterine cavity without spreading to healthy tissue or without leakage for the duration of treatment, enabling penetration beyond the superficial layer. Instant specification discloses an apparatus/system for delivering therapeutic agents, but only disclosed working example wherein TCA passed through the apparatus/system (See Table 1). There is no working example wherein a gel-form composition comprising TCA in presence of any thickening agent is applied to a tissue or subject for the treatment of chemical ablation. There is no measurement of viscosity for TCA gel formulation comprising TCA and thickening agent. There is no working example wherein composition comprising TCA and any thickening agent remains on the tissue or target surface without leaking/spreading and penetrates a tissue beyond a superficial layer that achieved alleged penetration depth over 3 millimeters. In absence of sufficient working example exhibiting the alleged intended result, instant specification does not provide adequate support for the claimed method for chemical ablation of endometrial and myometrial layers of a uterine cavity. The specification does not clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed. Applicant is reminded that MPEP 2161 II makes clear that “ The written description requirement is separate and distinct from the enablement requirement”. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 41, 43, 45, 65, and 70-80 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention (newly applied as necessitated by amendment). Claim 41 is amended with limitations that are generally narrative and replete with ambiguous, relative and functional terms that lack reasonably ascertainable boundaries, e. g. “enhancing ablation of the layers”, “enabling control of flow”, “enabling penetration beyond the superficial layer”, etc. The limitation of a thickening agent to provide “a viscosity greater than a viscosity of water” and “the viscosity enabling control of flow...” are indefinite. It’s not clear what objective value of viscosity would enable the said control of flow and enable the penetration beyond the superficial layer. One of ordinary skilled in the art would not be reasonably apprised of the extent/scope of the claimed viscosity. Claim 41 recites “chemical ablation of endometrial and myometrial layers of a uterine cavity, comprising applying to tissue a gel-form composition containing a therapeutic agent in the form of a trichloroacetic acid as an active ingredient in an aqueous solution...”. Uterine cavity is a hollow space lined with endometrium and myometrium is the muscular wall of the uterus, not a layer of the uterine cavity. It’ not clear what tissue is the gel form composition is applied to. “the therapeutic agent remaining on the tissue to penetrate the tissue beyond the superficial layer” is very confusing. “the superficial layer” lacks antecedent base and it’s not clear what tissue the therapeutic agent remains on and what tissue is beyond the superficial layer. As such, the lack of clarity render claim 41 indefinite, since the limitations do not clearly set forth the metes and bounds of the patent protection desired. Claims 43, 45, 65, and 70-80 are rejected due to dependency on claim 41. Further, claims 43, 45, 71, 75 and 76 recite “the agent” while claim 41 recites “therapeutic agent “ and “thickening agent”. It’s not clear which “agent” in these dependent claims refers to. Claim 70 depends on claim 61 which is now cancelled. Claim 71 depends on claim 48 which is now cancelled. If the base claim has been canceled, a claim which is directly or indirectly dependent thereon should be rejected as incomplete. See MPEP 608.01(n). Claim 70 is amended to recite wherein the viscosity exceeds a viscosity of CO2 gas. New claim 74 recites the viscosity exceeds a viscosity of saline utilized for injection into the cavity in a uterine cavity check. It’s not clear what concentration of saline and viscosity thereof is utilized for injection into the cavity in a uterine cavity check. The term “exceeds” is a relative term which renders the claim indefinite because viscosity of CO2 gas and saline vary significantly at different temperature, pressure, concentration, etc. which are not specified in the claims. In absence of specified/definite viscosity value against which instant claimed composition can be compared, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Claims 73 recites the composition is applied to conform to a target surface of the uterine cavity. Claim 76 recites the composition is applied to conform to an outer tissue layer of the uterine cavity. It’s not clear what degree of conformity is required. The claims do not provide an objective standard to determine the applied composition sufficiently “conform” to the surface and or outer tissue layer of the uterine cavity. It’s also not clear what an outer tissue layer in claim 76 is referred to. Claim 75 recites “after a period of time”. It’s not clear how long is “a period of time”, minutes, hours, days or months? Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 41, 43, 45, 65, and 70-80 are rejected under 35 U.S.C. 103 as being unpatentable over Hendriks et al. (US20130210776A1) in view of Shikhman et al. ( US20180133446A1, hereafter “Shikhman’ 446”, corresponding to US 10485962 B2, Applicant’s IDS dated 11/10/2023) and Kucukozkan et al. (International Journal of Gynecology & Obstetrics Volume 84, Issue 1, January 2004, pages 41-46 https://doi.org/10.1016/S0020-7292(03)00337-0, Chemical ablation of endometrium with trichloroacetic acid)(reapplied as necessitated by amendment). Hendriks teaches composition comprising active agent (e.g. trichloroacetic acid TCA) and at least one thickener, an applicator comprising aforementioned composition and method of treating variety of lesions with aforementioned composition, e.g. skin hyperpigmentation, acne, keratosis pilaris, actinic keratosis, mouth ulcers, eyelid xanthelasma, etc. (See abstract, Examples 1-8, claims 1-15). Regarding the active agent, Hendriks teaches composition comprises trichloroacetic acid TCA in the range of 0.1-50% w/w and concentrations higher than 50% TCA w/w are also effective (See [0008][0017])(which also read on instant claim 77 and 79). Hendriks teaches TCA effective for treating disorder caused by HPV (See [0004]). Regarding the thickening agent, Hendriks teaches variety of thickeners, e.g. polysaccharide thickener, crosslinked acrylic acid polymer and polysiloxanes, or mixtures thereof at various concentration (See [0018]-[0021], Examples 1-8). Hendriks teaches the thickener provides the composition with an increased viscosity, making it easier to focus the active ingredient on the intended location, preventing the spreading of the composition to locations where its action is not desired. Also, the thickener improves the time the active ingredient remains on a treated surface, improving the efficacy of the composition, etc. (See [0011], [0052]). Regarding the pH limitation, Hendriks teaches composition has a pH below 4, e.g. pH <2 ( See [0016], Examples 1-8). Hendriks explicitly teaches embodiments wherein pH<2 (See Example 4). Regarding the viscosity limitation of claim 41, 70 and 74, Hendriks teaches various viscosity, e.g. the composition has a viscosity of at least 3000 mPas as measured using rotary viscometry at 25 degree (See [0012]-[0015], Examples 2-7, claims 2-4)(which is considered as greater than viscosity of water and exceeds CO2 and saline as recited in claim 70 and 74). Regarding claims 45 and 72, Hendriks teaches composition may be applied by using a suitable applicator and applicator device comprising the composition (See [0014], [0024], [0044]-[0045], claim 13). Regarding claim 65, Hendriks teaches the thickener comprises Carbopol® which shows an excellent stability in the presence of TCA, allowing for colorless compositions, or excellent color control in case the composition comprises a colorant. Carbopol polymers, also called carbomers, are polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol (See [0019][0021], claim 10 ). Hendriks further teaches Carbopol allows for an excellent control of the viscosity of the formulation, in the range of 0.5-3% w/w (See [0022], claim 11)(which also reads on instant claim 41). Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. MPEP 2144.05. Hendriks collectively method of treating variety of conditions at different tissue/locations with composition comprising trichloroacetic acid (TCA) and thickener. Hendriks is silent about chemical alation of endometrial and myometrial layers of uterine cavity. Shikhman’ 446 teaches a system/apparatus and method for delivering therapeutic agents to a patient, e.g. a uterine cavity for endometrial ablation(See [0002], [0015], [0044], claims 1-20). Shikhman’ 446 teaches the therapeutic agent is a chemical agent for endometrial ablation (See [0013]) and explicitly teaches trichloroacetic acid (TCA) or derivative delivered into uterine cavity for chemical endometrial ablation, wherein TCA causes chemical cauterization on contact with tissue, but does not spread beyond where it is directly applied (See [0044])(which reads on instant claim 41). Regarding claims 43, 45, 72 and 75, Shikhman’ 446 teaches the therapeutic agent is preferably injected at a controlled pressure to maximize the surface of exposure of the endometrium to the agent while preventing leakage to other areas (See [0012]-0013], claims 1, 3, 5, 9, 13 and 15-16). Shikhman’ 446 also teaches use of CO2 and/or saline in the pressure control system (See [0069], [0073])(which reads on claim 70 and 74). Shikhman’ 446 teaches the agent /liquid evacuated after cavity check/test is complete(See 0072]). Regarding claims 73 and 76, Shikhman’ 446 teaches dispensing member can be configured so that it conforms to the contour /shape of the uterus (See [0064]). The difference between Shikhman’ 446 and instant claimed invention is the composition comprising thickener agent which was already taught by Hendriks. It would have been prima facie obvious to one of ordinary skilled in the art before the effective filing date of instant invention to incorporate the composition comprising TCA and thickening agent taught by Hendriks as the therapeutic agent in the method of chemical endometrial ablation taught by Shikhman’ 446, together with exploration/optimization based on general knowledge of tissue treatment (e.g. endometrial ablation, etc.), and arrive at the instantly claimed invention with reasonable expectation of success. Before the effective filing date of instant claimed invention, it was already known TCA could be delivered to uterine cavity for endometrial ablation through a pressurized system/apparatus as taught by Shikhman’ 446. Hendriks teaches composition comprising trichloroacetic acid (TCA) and thickener (e.g. Carbopol) in various amount and variety of viscosity. Trichloroacetic acid (TCA) is a well-established chemical cauterizing agent in dermatology and gynecology as taught by Hendriks and Shikhman’ 446. A person of ordinary skill in the art would be motivated to combine the teachings of Hendriks and Shikhman’ 446 because Hendriks teaches the composition comprising TCA and thickeners could provide desired viscosity for TCA to remain at target tissue. Shikhman’ 446 and Hendriks are silent about the penetration depth into the tissue as recited in claims 41 and 71. The penetration depth is construed as the intended function/result of active step of applying the composition comprising the therapeutic agent which does not necessarily further limit the method claim. As stated in MPEP 2111.04: In Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005), the court noted that a "‘whereby clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited.’" Id. (quoting Minton v. Nat’l Ass’n of Securities Dealers, Inc., 336 F.3d 1373, 1381, 67 USPQ2d 1614, 1620 (Fed. Cir. 2003)). Further, the penetration efficacy is the property of the therapeutic agent (TCA). Kucukozkan teaches endometrial ablation by 95% TCA may readily be performed as an alternative treatment method in the management of dysfunctional uterine bleeding DUB(See abstract). A skilled artisan would have known to explore the concentration of TCA (and thickening agent ) and control the penetration depth through experimentation/ optimization based on the general knowledge of TCA and endometrial ablation to achieve optimum treatment outcome. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. MPEP 2144.05. One of ordinary skill in the art would have had reasonable expectation of success in producing the claimed invention based on the combined teachings of prior art and general knowledge of TCA and tissue treatment/chemical ablation . Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Response to Arguments Applicant's arguments have been fully considered, but they are not persuasive. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Although Hendriks is silent about use of TCA for chemical ablation, Shikhman’ 446 explicitly teaches TCA could be delivered to uterine cavity for endometrial ablation through a pressurized system/apparatus. Hendriks explicitly teaches the thickener provides the composition with an increased viscosity, making it easier to focus the active ingredient on the intended location, preventing the spreading of the composition to locations where its action is not desired. Also, the thickener improves the time the active ingredient remains on a treated surface, improving the efficacy of the composition, etc. A skilled artisan would be motivated to apply Hendriks gel formulation of TCA comprising thickener for chemical ablation and reasonably expect TCA gel with desired viscosity would remain on the target surface without leaking/spreading to healthy tissues during treatment. Regarding the component of TCA formulation, Applicant argues Hendriks teaches away from TCA concentrations over 50% , stating TCA concentrations over 50% were found to significantly increase the chance of skin irritation... (Remarks, page 11-13). RESPONSE: Applicant’s argument is fully considered, but NOT persuasive. Please note “teaching away” can be a high bar and is usually not met by mere disclosure of alternatives or even a description that some teaching is somewhat inferior. MPEP § 2143(E) and §2143.01(I); In re Gurley, 27 F.3d 551 (Fed. Cir. 1994); In re Fulton, 391 F.3d 1195, 1201 (Fed. Cir. 2004); Galderma Labs. v. Tolmar, Inc., 737 F.3d 731, 738 (Fed. Cir. 2013); Bayer Pharma AG v. Watson Labs., Inc., 874 F.3d 1316, 1327 (Fed. Cir. 2017). Citing In re Gurley and In re Fulton, the Federal Circuit reiterated the proper standard for teaching away as follows: a reference will teach away when it suggests that the developments flowing from its disclosures are unlikely, reasonably, to produce the objective of the applicant’s invention. A statement that a particular combination is not a preferred embodiment does not teach away absent clear discouragement of that combination. See Syntex (U.S.A.) LLC v. Apotex, Inc., 407 F.3d 1371, 1380 (Fed. Cir. 2005). Hendriks teaches composition comprising trichloroacetic acid (TCA) in various amount (e.g. 40%) and teaches >50% TCA is effective for treating variety of disease/conditions. TCA concentrations over 50% increase the chance of skin irritation which is desirable feature for chemical endometrial ablation in instant case. A skilled artisan would have known chemical endometrial ablation might require higher concentration of TCA to destroy endometrium layer, e.g. 95% taught by Kucukozkan. Mustafa Kucuk (2005) also teaches 95% TCA is effective endometrial ablation for treatment of dysfunctional uterine bleeding. Thus, application of higher concentration of TCA for chemical endometrial ablation is within the general knowledge of a skilled artisan. Applicant also argues Hendriks teaches away from composition of greater than 3% w/w thickening agent (Remarks, page 14-15). RESPONSE: As Applicant agrees, Hendriks teaches embodiments comprising thickening agent carboxymethylcellulose at 4% (Example 3) which is greater than 3%. As elaborated above, reference teaching preferred embodiments/working examples comprising lower than 3% w/w Carbopol® is not considered “teaching away”. Hendriks teaches composition comprising trichloroacetic acid (TCA) and thickener (e.g. Carbopol®) in various amount , at various pH and variety of viscosity. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. MPEP 2144.05. A skilled artisan would have known to explore/ optimize the TCA gel composition for desired viscosity based on combined teachings of prior art, together with general knowledge of pharmaceutical composition and endometrial ablation to achieve optimum treatment outcome. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 41, 43, 45, 65, and 70-80 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10485962 B2 in view of Hendriks et al. (US20130210776A1). Reference claims are directed to an apparatus/system for delivering a therapeutic agent to a uterine cavity of a patient wherein therapeutic agent is a chemical ablative agent in contact with endometrium for endometrial ablation without leakage. Reference claims recite pressured injection system comprising storage unit that read on instant claims 43, 45 and 72. Reference are silent about the composition comprising thickening agent. It’s common practice to formulate therapeutic agent into composition in the pharmaceutical industry. The collective teachings of Hendriks is elaborated in preceding 103 rejection and applied as before. Hendriks collectively method of treating variety of conditions at different tissue/locations with composition comprising trichloroacetic acid (TCA) and thickener at variety of viscosity. It would have been prima facie obvious to one of ordinary skilled in the art to incorporate the composition comprising TCA and thickening agent taught by Hendriks as the therapeutic agent in the pressured injection system for chemical endometrial ablation taught by reference. Reference claims provide a roadmap for a method of endometrial ablation by utilizing a pressured injection in delivering therapeutic agent into uterine cavity (beyond a superficial level). A skilled artisan would be motivated to combine the teaching of Hendriks and reference claims and reasonably expect TCA composition with desired viscosity could be delivered into uterine cavity (beyond a superficial level) for endometrial ablation and remain at the target area without leakage. The instant application shares one common inventor/applicant with the reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Claims 41, 43, 45, 65, and 70-80 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 11813423B2 in view of Hendriks et al. (US20130210776A1). Reference claims are directed to an apparatus/system for delivering a pressurized ablation liquid to a uterine cavity of a patient wherein the liquid is a chemical ablative agent in contact with endometrium for endometrial ablation without leakage. Reference claims recite pressure controlled injection system that read on instant claims 43, 45 and 72. Reference are silent about the liquid/composition comprising thickening agent. The collective teachings of Hendriks is elaborated in preceding 103 rejection and applied as before. Hendriks collectively method of treating variety of conditions at different tissue/locations with composition comprising trichloroacetic acid (TCA) and thickener at variety of viscosity. It would have been prima facie obvious to one of ordinary skilled in the art to incorporate the composition comprising TCA and thickening agent taught by Hendriks as the therapeutic agent in the pressured injection system for chemical endometrial ablation taught by reference. Reference claims provide a roadmap for a method of endometrial ablation by utilizing a pressured injection in delivering therapeutic agent into uterine cavity (beyond a superficial level). A skilled artisan would be motivated to combine the teaching of Hendriks and reference claims and reasonably expect TCA composition with desired viscosity could be delivered into uterine cavity (beyond a superficial level) for endometrial ablation and remain at the target area without leakage. The instant application shares one common inventor/applicant with the reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LIYUAN MOU whose telephone number is (571)270-1791. The examiner can normally be reached Mon-Fri 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached on (571)272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.M./ Examiner, Art Unit 1628 /JARED BARSKY/ Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Jul 05, 2023
Application Filed
May 19, 2025
Response after Non-Final Action
Jun 11, 2025
Response after Non-Final Action
Mar 12, 2026
Non-Final Rejection mailed — §103, §112, §DP
Jun 19, 2026
Response Filed
Aug 28, 2026
Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767675
STRUCTURED MOLECULAR VECTORS FOR ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF
5y 2m to grant Granted Oct 20, 2026
Patent 12758544
New Pharmaceutical Formulation
4y 8m to grant Granted Oct 13, 2026
Patent 12758487
METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
2y 4m to grant Granted Oct 13, 2026
Patent 12708604
Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof
5y 2m to grant Granted Aug 18, 2026
Patent 12692254
BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES
5y 5m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+59.9%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 121 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month